{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:58:23Z","timestamp":1787795903172,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.msard.2019.03.017","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:24:36Z","timestamp":1553613876000},"page":"65-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing"],"prefix":"10.1016","volume":"31","author":[{"given":"John F.","family":"Foley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Goelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelene","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan R.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2019.03.017_bib0001","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201700108","article-title":"Protein turnover in aging and longevity","volume":"18","author":"Basisty","year":"2018","journal-title":"Proteomics"},{"key":"10.1016\/j.msard.2019.03.017_bib0002","unstructured":"Biogen. 2015. Prescribing Information [online]. Cambridge, MA: Biogen, Inc."},{"key":"10.1016\/j.msard.2019.03.017_bib0003","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2019.03.017_bib0004","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2019.03.017_bib0005","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.03.017_bib0006","doi-asserted-by":"crossref","first-page":"e34103","DOI":"10.1371\/journal.pone.0034103","article-title":"Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis","volume":"7","author":"de Andres","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2019.03.017_bib0007","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jns.2011.10.005","article-title":"CD49d expression as a promising biomarker to monitor natalizumab efficacy","volume":"314","author":"Defer","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2019.03.017_bib0008","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1212\/NXI.0000000000000388","article-title":"alpha4-integrin receptor desaturation and disease activity return after natalizumab cessation","volume":"4","author":"Derfuss","year":"2017","journal-title":"Neurol. Neuroimmunol. neuroinflamm."},{"key":"10.1016\/j.msard.2019.03.017_bib0009","article-title":"Natalizumab kinetics and dose extension: defining the therapeutic envelope","author":"Foley","year":"2012","journal-title":"Am. Acad. Neurol."},{"key":"10.1016\/j.msard.2019.03.017_bib0010","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.03.017_bib0011","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1177\/1352458512439438","article-title":"MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis","volume":"18","author":"Grimaldi","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.03.017_bib0012","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jneuroim.2011.03.001","article-title":"Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells","volume":"234","author":"Harrer","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2019.03.017_bib0013","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2019.03.017_bib0014","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/jcph.894","article-title":"Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis","volume":"57","author":"Muralidharan","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2019.03.017_bib0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.03.017_bib0016","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.03.017_bib0017","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.56.2.4","article-title":"Aging biology and geriatric clinical pharmacology","volume":"56","author":"McLean","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.msard.2019.03.017_bib0018","series-title":"Interpreting and Visualizing Regression Models Using Stata","author":"Mitchell","year":"2012"},{"key":"10.1016\/j.msard.2019.03.017_bib0019","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ana.20859","article-title":"Natalizumab effects on immune cell responses in multiple sclerosis","volume":"59","author":"Niino","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2019.03.017_bib0020","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.0000000000004485","article-title":"Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients","volume":"89","author":"Plavina","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.03.017_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2019.03.017_bib0022","article-title":"Monitoring CD49d receptor occupancy: a method to optimize and personalize natalizumab therapy in multiple sclerosis patients","author":"Punet-Ortiz","year":"2017","journal-title":"Cytometry Part B Clin. Cytom."},{"key":"10.1016\/j.msard.2019.03.017_bib0023","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ab.2011.01.001","article-title":"Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody","volume":"411","author":"Rispens","year":"2011","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.msard.2019.03.017_bib0024","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12974-016-0635-2","article-title":"New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies","volume":"13","author":"Sehr","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2019.03.017_bib0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1527-3458.2007.00003.x","article-title":"Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases","volume":"13","author":"Stuve","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.msard.2019.03.017_bib0026","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00415-015-7655-1","article-title":"Body weight-based natalizumab treatment in adult patients with multiple sclerosis","volume":"262","author":"Tanaka","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.03.017_bib0027","article-title":"Comparison of nadir serum concentrations in the extended dosing therapy of natalizumab between American and Japanese multiple sclerosis patients","volume":"2","author":"Tanaka","year":"2016","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2019.03.017_bib0028","article-title":"The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing","author":"van Kempen","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.03.017_bib0029","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/ane.12182","article-title":"Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?","volume":"129","author":"Wipfler","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2019.03.017_bib0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1352458510383075","article-title":"Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment","volume":"17","author":"Wipfler","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.03.017_bib0031","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2019.03.017_bib0032","article-title":"Natalizumab extended interval dosing is associated with a reduction in progressive multifocal leukoencephalopathy risk in the TOUCH\u00ae registry","author":"Zhovtis Ryerson","year":"2018","journal-title":"Am. Comm. Treat. Res. Mult. Scler."},{"key":"10.1016\/j.msard.2019.03.017_bib0033","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819301361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819301361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:35Z","timestamp":1761900335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819301361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":33,"alternative-id":["S2211034819301361"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.03.017","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}